Form 4: Akoya Biosciences Chief Legal Officer Reports Equity Dispositions Following Quanterix Merger

Jennifer Kamocsay, Chief Legal Officer of Akoya Biosciences, Inc., reported the disposition of common stock and employee stock options as Akoya Biosciences merged into a wholly-owned subsidiary of Quanterix Corporation on July 8, 2025.

Summary

• Akoya Biosciences, Inc. merged with and into Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, on July 8, 2025, with Akoya Biosciences, Inc. surviving as a wholly-owned subsidiary of Quanterix Corporation.
• Each outstanding share of Akoya common stock was converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash.
• Unvested Akoya restricted stock units (RSUs) were automatically converted into the right to receive the Per Share Merger Consideration upon vesting, subject to their original terms.
• Employee stock options to purchase Akoya common stock with an exercise price equal to or greater than the Per Share Merger Consideration were automatically terminated and cancelled for no consideration.
• Jennifer Kamocsay, Chief Legal Officer, disposed of 16,772 shares of common stock and 162,500 unvested restricted stock units, and had 75,000 employee stock options (exercise price $7.6) and 70,000 employee stock options (exercise price $5.35) terminated for no consideration.

Sentiment

Score: 6

Explanation: The document reports a completed merger, which is a significant corporate event. While the termination of some options for no consideration is negative for the reporting person, the overall event (merger) is a strategic move. The sentiment is neutral to slightly positive as it represents a definitive outcome for Akoya shareholders, integrating into a larger entity.

Positives

• The merger provides Akoya Biosciences shareholders with a combination of Quanterix stock and cash, offering liquidity and continued equity exposure to the combined entity.
• The conversion of unvested restricted stock units (RSUs) into the right to receive merger consideration upon vesting allows RSU holders to benefit from the merger terms.

Negatives

• Employee stock options with an exercise price equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration, resulting in a loss of potential value for option holders.
• Jennifer Kamocsay, as Chief Legal Officer, had 75,000 employee stock options with an exercise price of $7.6 and 70,000 employee stock options with an exercise price of $5.35 terminated for no consideration.

Risks

• The Per Share Stock Consideration and Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement, introducing potential variability in the final value received by shareholders.
• The termination of out-of-the-money or at-the-money stock options for no consideration represents a loss for the affected option holders.

Future Outlook

The document primarily reports a completed transaction. It notes that the Per Share Stock Consideration and Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement, indicating a potential for future adjustments based on the agreement's clauses.

Industry Context

This merger signifies consolidation within the life sciences or diagnostics industry, where companies like Akoya Biosciences (spatial biology) and Quanterix Corporation (ultra-sensitive protein detection) are combining to potentially leverage complementary technologies, expand market reach, or achieve operational synergies. Such mergers are common strategies for growth and market positioning in the highly competitive biotech and diagnostics sectors.

Comparison to Industry Standards

• This document reports a specific merger transaction and insider holdings changes, not financial performance. Therefore, a direct comparison to industry standards for financial results or operational benchmarks is not applicable.
• The merger consideration terms (0.1461 Quanterix shares + $0.38 cash per Akoya share) reflect the negotiated value of Akoya Biosciences within the context of the acquisition by Quanterix. Without specific financial details of the companies leading up to the merger, it is not possible to assess if the acquisition price was 'standard' for the industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Akoya): Received a combination of Quanterix stock and cash for their shares, providing liquidity and continued exposure to the combined entity.
• Shareholders (Quanterix): Potential for dilution from issuing new shares for the acquisition, but also potential for strategic benefits from integrating Akoya's technology and market.
• Employees (Akoya): Unvested RSUs converted to rights to receive merger consideration, but options with high exercise prices were cancelled for no consideration. Overall employment status and future roles within the combined entity are not detailed but are implied to be subject to integration plans.
• Management (Akoya): Their equity holdings were converted or cancelled as per the merger terms. Their roles within the new subsidiary structure are implied to change.

Next Steps

• Integration of Akoya Biosciences as a wholly-owned subsidiary into Quanterix Corporation.
• Potential adjustments to the Per Share Stock Consideration and Per Share Cash Consideration as per the Merger Agreement terms.
• Vesting of Rollover RSUs and subsequent receipt of Per Share Merger Consideration.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Corporate Acquisition, Jennifer Kamocsay, AKYA, QTRX